SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-043170
Filing Date
2023-11-30
Accepted
2023-11-30 11:45:17
Documents
14
Period of Report
2023-11-30
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44926
2 ex3-1.htm EX-3.1 19008
3 ex99-1.htm EX-99.1 16210
  Complete submission text file 0001493152-23-043170.txt   265926

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE zvsa-20231130.xsd EX-101.SCH 3012
5 XBRL LABEL FILE zvsa-20231130_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE zvsa-20231130_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3532
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 231454646
SIC: 2834 Pharmaceutical Preparations